Conversely, lung adenocarcinoma expression of CD166/ALCAM correlated with an improved prognosis (Figure 3, C and D).These results suggest that CD6 interactions with CD6 ligands that are expressed on cancer cells have an important influence on clinical outcomes of cancer patients and point to the CD6/CD6 ligand axis as a potential new therapeutic target in cancer treatment. This evidence concerns the gene ALCAM and lung adenocarcinoma.